Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma

Manini, M.A.; Sangiovanni, A.; Fornari, Fabio; Piscaglia, Fabio; Biolato, Marco; Fanigliulo, L.; Ravaldi, E.; Colombo, Massimo

doi:10.1016/j.jhep.2014.01.006

Cited by 58 publications

(39 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RFA effi cacy was evaluated using enhanced dynamic triphasic computed tomography or contrast-enhanced ultrasound at 1 month aft er the ablation, according to the modifi ed WHO and related criteria (27)(28)(29). All imaging evaluations were performed at the treatment center and were reported by two independent experienced abdominal radiologists.…”

Section: Assessment Of Treatment Effi Cacymentioning

confidence: 99%

Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage 0–B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

Feng

et al. 2014

American Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Assessment Of Treatment Effi Cacymentioning

confidence: 99%

Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage 0–B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

Feng

et al. 2014

American Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Indeed, these recommendations are based more on expert opinions than controlled studies. Only a few single‐centre studies have prospectively validated these recommendations. Moreover, apart from the studies by Khalili et al., Sangiovani et al.…”

Section: Introductionmentioning

confidence: 99%

EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice

Aubé

Oberti

Lonjon

et al. 2017

Liver International

106

View full text Add to dashboard Cite

show abstract

“…The sequential approach to hepatic lesions leads to a decreased need for liver biopsies when evaluating nodules between 1 and 2 cm, and also reduces costs when compared with lesions > 2 cm [50] .…”

Section: Eastern Guidelines (Apasl and Jsh)mentioning

confidence: 99%

Diagnosis and treatment of hepatocellular carcinoma: An update

Tejeda-Maldonado¹

2015

WJH

105

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignancies leading to high mortality rates in the general population; in cirrhotic patients, it is the primary cause of death. The diagnosis is usually delayed in spite of at-risk population screening recommendations, i.e., patients infected with hepatitis B or C virus. Hepatocarcinogenesis hinges on a great number of genetic and molecular abnormalities that lead to tumor angiogenesis and foster their dissemination potential. The diagnosis is mainly based on imaging studies such as computed tomography and magnetic resonance, in which lesions present a characteristic classical pattern of early arterial enhancement followed by contrast medium "washout" in late venous phase. On occasion, when imaging studies are not conclusive, biopsy of the lesion must be performed to establish the diagnosis. The Barcelona Clinic Liver Cancer staging method is the most frequently used worldwide and recommended by the international guidelines of HCC management. Currently available treatments include tumor resection, liver transplant, sorafenib and locoregional therapies (alcoholization, radiofrequency ablation, chemoembolization). The prognosis of hepatocarcinoma is determined according to the lesion's stage and in cirrhotic patients, on residual liver function. Curative treatments, such as liver transplant, are sought in patients diagnosed in early stages; patients in more advanced stages, were not greatly benefitted by chemotherapy in terms of survival until the advent of target molecules such as sorafenib. Core tip: This paper reviews the most recent evidence on hepatocarcinoma including its molecular pathogenesis and prognosis, with special emphasis on its diagnosis, staging and treatment. The most recent Easter and Western international guidelines are also reviewed.

show abstract

Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma

Cited by 58 publications

References 16 publications

Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage 0–B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage 0–B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice

Diagnosis and treatment of hepatocellular carcinoma: An update

Contact Info

Product

Resources

About